Safety and efficacy of venetoclax plus LDAC in treatment-naive AML patients aged ≥ 65 years
SPIRIT2 trial on dasatinib for AML - safety and side effect management
Midostaurin: a step forward in the treatment of FLT3-mutated AML
How can networking aid acute leukemia patients in developing countries?
Nivolumab in combination with azacitidine in patients with relapsed acute myeloid leukemia (AML)
Naval G. Daver